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ABSTRACT 
Rationale: Negative circumferential resection margins (CRM) are the cornerstone for curative treatment 
of locally advanced rectal cancer (LARC). However, in up to 18.6% of patients tumor-positive resection 
margins are detected upon histopathology. In this proof-of-concept study, we investigated the feasibility of 
optical molecular imaging as a tool to evaluate the CRM directly after surgical resection in order to improve 
tumor-negative CRM rates. Methods: LARC patients that were treated with neoadjuvant 
chemoradiotherapy received an intravenous bolus injection of 4.5 mg bevacizumab-800CW, a fluorescent 
tracer targeting vascular endothelial growth factor A (VEGFA), 2-3 days before surgery (NCT01972373). 
To evaluate the CRM status, back-table fluorescence-guided imaging (FGI) was performed of the fresh 
surgical resection specimens (N = 8). These results were correlated to histopathology. Secondly, to 
determine the sensitivity and specificity of bevacizumab-800CW for tumor detection, a mean fluorescence 
intensity (MFI) cut-off value was determined on the formalin-fixed tissue slices (N = 42; 17 patients). Local 
bevacizumab-800CW accumulation was evaluated by fluorescence microscopy. Results: Back-table FGI 
correctly identified a tumor-positive CRM by high fluorescence intensities in one of two patients (50%) 
with a tumor-positive CRM. The other patient showed low fluorescence intensities, although (sub-
)millimeter tumor deposits were present <1 mm of the CRM. FGI correctly identified 5/6 tumor-negative 
CRMs (83%). The one patient with false-positive findings had a marginal negative CRM of only 1.4 mm. 
ROC analysis of fluorescence intensities of formalin-fixed tissue slices gave an optimal MFI cut-off value 
for tumor detection of 5,775 (sensitivity and specificity of 96.16% and 80.39% respectively). Bevacizumab-
800CW enabled a clear differentiation between tumor and normal tissue up to a microscopic level, with a 
tumor-to-background ratio of 4.7 ± 2.5 (mean ± SD). Conclusion: In this proof-of-concept study, we 
showed the potential of back-table FGI to evaluate the CRM status in LARC patients. Optimization of this 
technique with adaptation of standard operating procedures could change perioperative decision-making 
with regard to extending resections or applying intraoperative radiation therapy in case of positive CRMs.  
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INTRODUCTION 
In today’s clinical practice, patients with locally advanced rectal cancer (LARC) receive long-course 
neoadjuvant chemoradiotherapy (nCRT) followed by surgical resection using the total mesorectal excision 
(TME) principles. nCRT induces tumor downsizing and downstaging, which facilitates complete resection 
by TME, resulting in significantly reduced local recurrence rates and increased opportunity for sphincter-
sparing resections (1-5).  
Obtaining negative circumferential resection margins (CRM) is key in rectal cancer therapy. The 
CRM has proven to be one of the most important predictors for local recurrence and to a lesser extent the 
development of distant metastases and survival (6). Restaging after nCRT occurs through a high-resolution 
MRI-scan for tumor staging and a CT-scan of thorax and abdomen for distant metastasis and lymph node 
staging (7-9). Accurate restaging can be highly challenging as differentiating between desmoplastic reaction 
and viable tumor tissue on preoperative imaging modalities is often difficult after nCRT.  
Intraoperatively, surgeons mainly rely on visual and tactile inspection for margin assessment and 
differentiation between tumor and healthy tissue. This is often inaccurate, especially after nCRT, as small 
tumor deposits are frequently present within fibrotic parts (10). When in doubt, resection margins can be 
evaluated intraoperatively by frozen section pathologic evaluation, but this is time-consuming, costly and 
poses a high risk of sampling error (11).  
Despite nCRT, TME-surgery and frozen section analysis, a tumor-positive CRM, defined as tumor 
presence 1 mm from the CRM, is detected in up to 18.6% of primary LARC surgeries upon final 
histopathology (7-9). Peri-operative resection margin evaluation using optical molecular imaging could 
improve negative CRM rates by extending resections, applying intraoperative radiation therapy (IORT) or 
more innovative treatment modalities like photo-immunotherapy of the wound bed (12). In contrast, when 
a margin is evaluated to be tumor-negative, extended resections could be avoided. 
The aim of this proof-of-concept study was to evaluate if back-table fluorescence-guided imaging 
(FGI) using the near-infrared fluorescent tracer bevacizumab-800CW, could aid in evaluating the CRM 
status at the surgical theater. Bevacizumab-800CW targets vascular endothelial growth factor A (VEGFA), 
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which is overexpressed in LARC as well as many other solid tumors (13-15). We retrospectively analyzed 
back-table FGI data of fresh surgical specimens of LARC patients that were treated with nCRT. This 
technique may eventually allow real-time determination of CRM during surgery, which could aid 
intraoperative clinical decision-making with regard to extending resections or applying IORT in case of a 
positive CRM, to improve the outcome of LARC patients. 
 
MATERIAL AND METHODS 
Study Design and Population 
Postoperative fluorescence imaging data were collected from 25 LARC patients enrolled in a 
clinical trial evaluating VEGFA-targeted fluorescence molecular endoscopy (Clinicaltrials.gov identifier: 
NCT01972373). Eligibility criteria included histologically proven LARC, with the inferior margin within 
16 cm from the anal verge and treatment with long-course nCRT. To determine if back-table FGI could aid 
in evaluating the CRM status, patients were included if fluorescence imaging data was available from at 
least the anterior and posterior sides of the fresh surgical specimen. Furthermore, to evaluate local 
bevacizumab-800CW accumulation and determine the sensitivity and specificity of bevacizumab-800CW 
for tumor detection using a fluorescence cut-off value, patients with high-resolution fluorescence images 
available of formalin-fixed tissue slices were included. The study was performed at the University Medical 
Center Groningen, approved by the Institutional Review Board (METc 2013/067) and all subjects signed a 
written informed consent.  
 
Surgery 
 After nCRT, all patients received an intended curative resection by either low anterior resection 
(LAR) for proximal rectum tumors or abdominal perineal resection (APR) for distal rectum tumors. 
Resections were extended outside the TME planes in case of tumor growth into adjacent organs. Patients 
only received IORT if judged necessary based on preoperative suspicion of mesorectal fascia involvement 
or intraoperative evaluation by the surgeons. 
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Histopathological Processing 
 Histopathological processing of surgical specimens was performed by a board-certified 
gastrointestinal pathologist. After gross pathology, CRMs were inked black and staple lines were removed. 
Specimens were anteriorly opened from proximal to distal, except for specimens with an anterior lesion, 
which were opened until the rectal fold. All specimens were formalin-fixated for at least 48 hours and 
serially sliced perpendicular to the rectum, from distal to proximal into ±0.5 cm thick tissue slices. Distal 
and proximal resection surfaces plus additional areas of interest (i.e. regions suspect for CRM involvement, 
perineural growth, vascular invasion, lymph nodes, etc.) were included for paraffin embedding. Formalin-
fixed paraffin-embedded (FFPE) tissue blocks were cut in 4 µm tissue sections and hematoxylin eosin (HE) 
stained for routine histopathological examination. Imunohistochemistry was performed if required. A 
tumor-positive CRM was defined as tumor presence 1 mm from the inked CRM, in accordance with the 
Dutch national guidelines.  
 
Bevacizumab-800CW 
 All patients received a 4.5mg IV bolus injection of bevacizumab-800CW (1 mg/ml) two-to-three 
days before surgery based on microdosing regulations (Fig. 1). Bevacizumab-800CW was produced under 
cGMP conditions at the University Medical Center Groningen, as described previously (16).  
 
Back-table FGI 
 To evaluate the CRM status, back-table FGI of the fresh surgical specimen was performed in a 
light-tight room directly after surgery using the Explorer Air fluorescence camera (SurgVision BV, 
Groningen, The Netherlands, Fig. 1). Areas with high fluorescence signals were marked with a pin and 
subsequently inked with a different color from the CRM during pathological processing, to ensure an 
accurate correlation of fluorescence with histopathology.  
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Fluorescence Imaging of Tissue Slices and Sections 
 To evaluate the local tracer accumulation, fluorescence imaging of both sides of all formalin-fixed 
tissue slices was performed using the Explorer Vault, a standardized and light-tight fluorescence imaging 
system (SurgVision BV, Groningen, The Netherlands). Thereafter, two-to-three tissue slices containing 
tumor and/or normal rectal tissue were imaged per patient using the high resolution Odyssey CLx 
fluorescence imaging system (LI-COR Biosciences Inc., Lincoln, NE; Fig. 1). Additional areas of interest 
based on fluorescence imaging were also paraffin embedded, sliced in 4 µm tissue sections and HE stained. 
All FFPE tissue blocks were fluorescently scanned using the Odyssey CLx (Fig. 1). For comparison 
purposes, all fluorescence images were thresholded to minimum-maximum values per imaging modality 
for each individual patient. 
To broaden our understanding of the overall penetration, distribution, and accumulation of 
bevacizumab-800W in rectal cancer tissue, a combination of optical tissue clearing and light-sheet 
fluorescence microscopy (LSFM) was performed on selected tissue slices, as previously described for 
preclinical tissue samples (Supplemental Material)(17).  
 
Fluorescence Grid Analysis 
 Finally, to evaluate the sensitivity and specificity of bevacizumab-800CW for tumor detection, a 
fluorescence grid analysis was used based on histopathology as a gold standard to determine a fluorescence 
cut-off value (Supplemental Material).  
 
Statistical Analysis 
Normally distributed data is presented as mean values with standard deviation (SD) and skewed 
data as median values with interquartile range (IQR). A receiver operating characteristics (ROC) curve was 
plotted to determine the MFI cut-off value for tumor detection. P-values <0.05 were considered statistically 
significant.  Statistical analyses were performed using Prism (version 7.0, GraphPad Software). 
 




In this retrospective proof-of-concept study, eight of 25 patients met the criteria to determine the 
feasibility of back-table FGI for the evaluation of the CRM status (Supplemental Fig. 1). For the second 
aim of this study, to evaluate local bevacizumab-800CW distribution and determine the sensitivity and 
specificity of bevacizumab-800CW for tumor detection on high-resolution tissue slices, 17/25 patients met 
the inclusion criteria (Supplemental Fig. 1). Patient characteristics are depicted in Table 1. All patients 
received 4.5 mg bevacizumab-800CW IV, 2-3 days prior to surgery. Ten patients underwent a LAR and 
seven patients an APR. There were no tracer-related (serious) adverse events in any of the patients.  
 
Evaluation of the CRM Status 
Of eight evaluated cases, two patients (25%) presented with a tumor-positive CRM on final 
histopathology. Back-table FGI correctly predicted the tumor-positive CRM in one of these patients due to 
increased fluorescence signals in the CRM (50%, Fig. 2). This patient was treated with an APR with en-
bloc resection of the sacrum and a wide perineal excision because of a fistula. Intraoperatively, two frozen 
section analyses were performed of the lateral resection surface, both of which were benign. Interestingly, 
during back-table FGI of the fresh surgical specimen, high fluorescence signals were observed at the lateral 
resection margin (Fig. 2A). Fluorescence imaging of the correscopnding tissue slice also showed high 
fluorescence that seemed to reach into the CRM, while the surrounding non-tumor tissue showed low 
fluorescence (Fig. 2B). Final histopathology proved that this exact location was a tumor-positive CRM (Fig. 
2C; orange arrows).  
The second patient with a tumor-positive CRM received a LAR. Back-table FGI of the fresh 
surgical specimen and subsequent fluorescence imaging of the tissue slices showed low fluorescence 
intensities in the CRM, apart from fluorescence in two enlarged suspicious lymph nodes that proved to be 
tumor-positive (Supplemental Fig. 2A). However, the pathologist reported a tumor-positive CRM that was 
solely based on the presence of isolated microscopic vital-looking tumor deposits of (sub-)millimeter size 
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within a distance of 0.2-1 mm of the CRM (Supplemental Fig. 2B; orange arrow). The tumor volume was 
limited due to the (sub-)millimeter size of the tumor deposits, which may explain the negative imaging 
results.  
Six out of 8 patients (75%) had a tumor-negative CRM, of which five were correctly predicted by 
low fluorescence intensities during back-table FGI (representative example in Supplemental Fig. 3). 
Subsequent fluorescence imaging of tissue slices also showed low fluorescence in relation to the CRM, 
although fluorescence was observed in the (intra)luminal tumor, except for the patient with a pathological 
complete response. IORT was applied to one of these patients due to a macroscopic suspicion of a tumor-
positive CRM, while histopathology showed a tumor-negative CRM (>1 cm).  
The remaining patient with a tumor-negative CRM received a low-anterior resection with en-bloc 
resection of the uterus, cervix, adnexa and the distal right ureter due to tumor ingrowth. Increased 
fluorescence was observed at the cervix during back-table FGI and subsequent fluorescence imaging of the 
tissue slices, potentially indicating a tumor-positive CRM. Although the fluorescence colocalized with a 
tumor deposit upon histopathology, the CRM was defined as tumor-negative, as the distance to the CRM 
was 1.4 mm. 
 
Fluorescence Cut-off Value and Local Bevacizumab-800CW Accumulation 
High-resulution fluorescence Odyssey scans of formalin-fixed tissue slices (n = 42) available from 
17 patients were used to determine a semi-quantitative fluorescence cut-off value for tumor detection. A 
total of 5,101 grid-squares were analyzed, of which 446 were classified as tumor-positive and 4,655 as 
tumor-negative (Figs. 3A-3C). Significantly higher fluorescence intensities were observed in tumor areas 
(median MFI: 12,000) compared to surrounding non-tumor tissue (median MFI: 2,140; P < 0.0001; Fig. 
3D), which resulted in a ratio between tumor-to-surrounding tissue of 4.7 ± 2.5 (mean ± SD). Receiver 
operating characteristics (ROC) curves were plotted per patient (Fig. 3E) and for all patients combined, 
with an area under the curve of 0.94 (std. error 0.0039; Fig. 3F). In our limited sample size, an optimal MFI 
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cut-off value of 5,775 was calculated using Youden’s J statistics (J = 0.77), with a sensitivity and specificity 
of 96.19% and 80.39% respectively. 
 Finally, we evaluated the distribution and accumulation of bevacizumab-800CW on a microscopic 
level. Bevacizumab-800CW was mainly localized in the micro-environment of the tumor cells (Fig. 4), 
which was in line with the expected location of VEGFA (Supplemental Video 1).  
 
DISCUSSION 
Accurate perioperative evaluation of resection margins is highly important for the prognosis of 
LARC patients. In this explorative study, we demonstrate for the first time the feasibility of  back-table FGI 
for identification of tumor-positive resection margins in LARC patients. Our data suggests that FGI may 
have the potential to guide current clinical decision-making with regard to additional targeted resections or 
application of IORT. Future studies using a standardized imaging protocol with larger patients samples 
should confirm these results. 
Over the past decade, optical molecular imaging has predominantly been applied for intraoperative 
guidance and surgical navigation. Two clinical studies have demonstrated the feasibility and potential 
benefit of fluorescence-guided surgery in colorectal cancer patients (18,19). However, fluorescence-guided 
surgery is subject to several limitations related to the currently available hardware, such as variation in 
image-acquisition parameters and interference of ambient light. Moreover, homogenous tracer excitation is 
difficult especially in rectal cancer surgery, as the pelvic region is a confined surgical field often situated 
deep in the patient. Possibly, the development of fluorescence laparoscopes and robotic systems sensitive 
enough to detect micro-dosed fluorescent tracers may enable more reliable intraoperative evaluation of 
rectal cancer resection margins in the future. 
Back-table FGI circumfents these limitations, as it makes use of a controlled, standardized and 
closed-field imaging environment that results in a consistent field-of-view, imaging distance and image-
acquisition parameters (20). This enables a highly sensitive and semi-quantitative evaluation of resection 
margins, within a maximum of one hour after specimen excision at the OR.  
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The potential added value of back-table FGI was clearly demonstrated by the patient in which a 
tumor-positive CRM was detected at the OR, while surgical assessment and frozen section analysis were 
false-negative. Although intraoperative frozen section analysis is recommended for low and mid rectal 
tumors, it is prone to sampling error, labor-intensive and significantly prolongs anesthesia (21,22). By 
‘bringing pathology to the operating theatre’ using back-table FGI, both surgeons and pathologist may be 
guided in correctly assessing the CRM status and evaluating the need for extended surgery or application 
of IORT, thereby improving personalized treatment. 
In rectal cancer surgery, caution is to be taken with unnecessarily extending TME surgery to a 
partial or total resection of adjacent pelvic organs or applying IORT, as this can result in substantial 
postoperative complications and is associated with the need for reinterventions (23). Back-table FGI 
correctly predicted five out of six tumor-negative CRMs, which might have prevented unnecessary IORT 
application in one patient. In contrast, one close margin of 1.4 mm was identified as tumor-positive based 
on fluorescence. Although currently a tumor-positive margin is defined as tumor cells 1 mm of the CRM, 
this definition is under debate, as both patients with a CRM of 0.0 - 1.0 mm and 1.1 – 2.0 mm are shown to 
have an equally increased 2-year risk of local recurrence and distant metastases (8,24). Application of 
fluorescence may highlight the location of a (potentially) tumor-positive CRM, which allows the surgeon 
to perform more ‘targeted’ intraoperative frozen section analysis.  
FGI may also support the pathologist by differentiating tumor from healthy tissue, i.e. fluorescence-
guided pathology. Currently, tissue sampling is performed by gross examination of the surgical specimen 
and tissue slices, which can be challenging as the tissue architecture is changed by nCRT. Using the 
fluorescence-grid analysis, we showed a tumor-to-background ratio of 4.7 ± 2.5 on tissue slices, with a high 
sensitivity (96.19%) and specificity (80.39%) for tumor detection. A fluorescence cut-off value provides 
more objective information and may enable targeted tissue sampling, potentially saving labor, time and 
money. In addition, the fluorescence grid analysis can be used to evaluate tracer biodistribution and can 
easily be implemented on other closed-field imaging devices.  
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This study has several limitations. First of all, the number of patients included for CRM evaluation 
was relatively low, as this was a retrospective proof-of-concept analysis of a clinical trial evaluating 
fluorescence molecular endoscopy (NCT01972373), and imaging techniques as well as ex vivo imaging 
procedures have developed throughout the study. Secondly, a dose-escalation was not incorporated in this 
study design. Currently available evidence from two bevacizumab-800CW dose-escalation studies suggests 
that increasing the dose above microdosing levels may result in higher tracer accumulation without 
significantly increasing background fluorescence (25,26). This may further improve the detection of tumor-
positive CRMs that are based on small tumor deposits, which proved to be challenging in one of our 
patients.  
We propose a standardized imaging protocol that can be used in future research and for the 
development of FGI, based on our findings in the current study and our recently reported analytical 
workflow (Figure 5)(26). Fluorescence imaging is performed at fixed time-points. First, when feasible, 
intraoperative fluorescence-guided surgery is performed. After resection, back-table FGI of the fresh 
surgical specimen is performed to evaluate the resection margin status, preferably using a closed-field 
imaging system. In case high fluorescence is observed during intraoperative or back-table FGI, several 
treatment options can be considered, such as frozen section analysis, an additional or extended resection, 
IORT or potentially more innovative treatment modalities like photo immunotherapy (12). Subsequently, 
to correlate fluorescence with histology, fluorescence imaging is performed during histopathological 
processing: of the fresh surgical specimen, formalin-fixed tissue slices and paraffin-embedded tissue 
sections. Additionally, fluorescence microscopy can evaluate local tracer accumulation. Alltogehter, this 
can give more insight in tissue biodistribution, important for tracer or drug development, or to evaluate 
potential off- and on-target effects of fluorescence tracers. We believe such a standardized imaging protocol 
is widely applicable for the validation of FGI in different tumor types and with different fluorescent tracers.  
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CONCLUSION 
Our study shows the potential of back-table FGI using the near-infrared fluorescent tracer 
bevacizumab-800CW targeting VEGFA for margin evaluation at the surgical theatre in patients with 
LARC. The technique itself proved to be safe, feasible and shows potential to guide perioperative clinical 
decision-making with a high sensitivity in patients with a threatened tumor-positive resection margin. A 
phase II study using a standardized imaging protocol is in development to confirm these results. Future 
studies will provide evidence if FGI will be beneficial for all patients, or will only be applied in selected 
cases to guide clinical decision-making.  
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KEY POINTS 
Question: Can back-table fluorescence-guided imaging (FGI) be used as a tool to evaluate the 
circumferential resection margin status at the operating theatre, to improve tumor-positive resection margin 
rates in locally advanced rectal cancer patients?  
Pertinent findings: In this explorative study, we demonstrate for the first time the potential of  back-table 
FGI for identification of tumor-positive resection margins in LARC patients. In addition, we provide a data 
collection and data analysis design for future studies evaluating the added value of optical molecular 
imaging for evaluation of resection margins.  
Implications for patient care:  Accurate intraoperative detection of tumor-positive resection margins by 
back-table FGI has the potential to improve clinical decision making in locally advanced rectal cancer with 
regard to extending resection margins or applying intraoperative radiation therapy. 
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TABLES AND FIGURES 
 
CRM evaluation 
(N = 8) 
No.              % 
Fluorescence cut-off 
value (N = 17) 
No.              % 
Sex 
    Male 














    Median (range) 
 
56 (54 - 61) 
 
56 (31 - 76) 
Duration between nCRT - Surgery (days) 






    Low-anterior resection 
- Including adjacent organs 
    Abdominoperineal resection 





















Intraoperative radiation therapy 
    Not standby 
    Standby 














    pT0 N0 M0 (pCR)    
    pT2 N0 M0 
    pT3 N0 M0 
    pT3 N1 M0  
    pT3 N2 M0 





























Circumferential resection margin (CRM) 
     1 mm (tumor-positive) 
    1-2 mm 
    > 2 mm 





















Distal resection margin 
     1 mm (tumor-positive) 
    1-2 mm 
    > 2 mm 






















Patient and tumor characteristics. nCRT = neoadjuvant chemoradiotherapy; pCR = pathological complete 
response; TNM = Tumor, Node, Metastasis. 






Schematic overview of study design. Bevacizumab-800CW (4.5 mg) was administered intravenously 2-3 
days prior to surgery. Fluorescence-guided imaging was performed at every step during pathological 
processing: back-table of the fresh surgical specimen, of the tissue slices and tissue sections. Results were 
correlated to histopathology.  
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 FIGURE 2 
Back-table FGI of a patient with a tumor-positive CRM, with a black pin at the location showing increased 
fluorescence, to enable an accurate correlation with histology (A, orange arrow). Fluorescence imaging of 
two corresponding tissue slices (B) and further microscopic fluorescence imaging and histological 
correlation (C), with orange arrows indicating the location of the tumor-positive CRM. High fluorescence 
is observed at the CRM of tissue slice 1 containing the tumor-positive CRM, whereas low fluorescence was 
observed in the non-tumor tissue slice 2, corresponding to the microscopy results. FFPE = formalin-fixed 
paraffing embedded; HE = hematoxylin eosin; N = non-tumor; T = tumor. 
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 FIGURE 3 
Fluorescence grid analysis. All tumor tissue was delineated on a hematoxylin eosin (HE)-staining (A) and 
subsequently overlaid on the high-resolution fluorescence images of tissue slices (B). Each 3-by-3 mm 
square was selected as tumor-positive (C, orange) or tumor-negative (C, green). Median fluorescence 
intensities (MFI) were calculated per square, with significantly higher fluorescence in tumor tissue 
compared to surrounding non-tumor tissue (12,000 versus 2,140; P < 0.001; D). Individual areas under the 
curve were determined per patient (E) and a receiver operating characteristic (ROC)-curve was plotted, 
showing an area under the curve (AUC) of 0.94 (F).  
 





Representative example of light-sheet fluorescence microscopy to evaluate the local tracer accumulation in 
a rectal cancer tissue slice, showing the tissue morphology based on autofluorescence (A), the fluorescence 
(B), an morphology and fluorescence overlay (C) and the corresponding histology (D). Magnified images 
are depicted in the bottom row. Increased bevacizumab-800CW binding can be seen in the micro-
environment of the tumor cells compared to surrounding normal mucosa and fibrosis. 
  




Proposed data collection and analysis design for resection margin evaluation, including intraoperative 
imaging to evaluate resection margins and identify potential lymph nodes and/or peritoneal metastasis, 
back-table imaging of the fresh surgical specimen to evaluate resection margins, and further fluorescence 
analysis of tissue slices, formalin-fixed paraffin-embedded (FFPE) tissue blocks and tissue sections for 
cross-reference and correlation of fluorescence with histology. T = tumor; HE = hematoxylin eosin; IHC = 
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MATERIAL AND METHODS 
Fluorescence Grid Analysis 
Tumor locations were delineated on 4 µm HE stained tissue sections by a board-certified 
gastrointestinal pathologist, who was blinded for fluorescence imaging results. The histological delineation 
was merged with the high-resolution fluorescence images of the formalin-fixed tissue slices (Odyssey CLx), 
to enable a direct correlation of fluorescence with histology. Subsequently, a fluorescence grid analysis was 
performed, which was adapted from Gao et al (1). A 3 x 3 mm grid was drawn on the merged image using 
ImageStudio software (version 5.0, LI-COR Biosciences Inc., Lincoln, NE, USA), dividing it into identical 
9 mm2 squares. Each square was classified as tumor-negative or tumor-positive if more than 20% of the 
square consisted of tumor-tissue, based on the histological delineation. ImageStudio software automatically 
calculated mean fluorescence intensities (MFI) for each square. A receiver operating characteristics (ROC) 
curve was determined per patient and for all patients combined, to determine an optimal cut-off value for 
tumor detection based on optimal sensitivity and specificity as determined by Youden’s J statistics.  
 
Three-Dimensional Tissue Analysis by Light-Sheet Fluorescence Microscopy. 
LSFM enables a multicolor 3D analysis of optical transparent whole-mount tissue specimen at 
cellular resolution. Tissue slices were formalin fixated, dehydrated, and incubated in an organic clearing 
solution (one-part benzylalcohol & two-parts benzylbenzoate, incubation condition: 24-48 hours, 4°C, dark) 
to obtain high optical tissue transparency. Subsequently, the fluorescence signal intensity of bevacizumab-
800CW as well as the tissue autofluorescence (providing detailed morphological tissue information) were 
measured within the cleared rectal cancer tissue using a commercially available light-sheet microscope 
(UltraMicroscope II, LaVision Biotec GmbH, Bielefeld, Germany). The obtained fluorescence imaging 
results were visualized as single and co-registered data sets, combining information of drug 
penetration/accumulation with morphological tissue context. In addition, the performed virtual 3D tissue 
analysis was also correlated to conventional histology.  
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Fluorescence imaging parameters 
Throughout the study, the same imaging parameters were used for data acquisition per imaging device. In 
case of saturation of fluorescence images, the fluorescence exposure time or gain was decreased to ensure 
adequate data collection. 
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High fluorescence 1 1* 2 
Low fluorescence 1** 5 6 
Total 2 6 8 
SUPPLEMENTAL TABLE 1  
Contingency table. A qualitative evaluation of fluorescence intensities was performed on the fresh surgical 
specimens. Low fluorescence was assessed as a homogenous background fluorescence; localized increased 
fluorescence was assessed as high fluorescence. *Distance to the circumferential resection margin (CRM) 
of 1.4 mm. **Tumor-positive CRM based on isolated microscopic tumor deposits  1 mm of the CRM.  
 
*Attachment* 
SUPPLEMENTAL VIDEO 1 
Three-dimensional light-sheet microscopy of bevacizumab-800CW fluorescence localized in tumor 
environment of a tissue slice containing tumor. Tissue slice histology is also depicted in Figure 4. The left 
tissue slice depicts the tissue morphology based on autofluorescence; the right tissue slice depicts the near-
infrared fluorescence image. 
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SUPPLEMENTAL FIGURE 1 
Flow diagram of the study. From 25 patients, eight patients were included in this explorative analysis for 
the use of back-table fluorescence-guided imaging to evaluate the circumferential resection margins (CRM) 
status on the fresh surgical specimens. Out of two tumor-positive margins, one was identified correctly using 
back-table, whereas the other was considered tumor-negative, despite the presence of (sub)millimeter tumor 
deposits <1 mm of the CRM. Five out of six tumor-negative CRMs were identified correctly. The remaining 
CRM was identified to be tumor-positive based, although the CRM was marginally negative CRM with 1.4 
mm. Seventeen patients were included to determine the sensitivity and specificity of bevacizumab-800CW 
and evaluate local tracer accumulation, including the eight patients included for CRM evaluation.  
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SUPPLEMENTAL FIGURE 2 
Tumor-positive CRM with low fluorescence intensities during back-table FGI of the fresh surgical specimen 
and fluorescence imaging of a subsequent tissue slice (A). The orange arrows indicate the location of the 
tumor-positive CRM that was based on isolated microscopic tumor deposits as determined on final 
histopathology (B). The asterix (*) indicates a tumor-positive lymph node. FFPE = formalin-fixed paraffin 
embedded; HE = hematoxylin eosin. 
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SUPPLEMENTAL FIGURE 3 
Tumor-negative CRM with low fluorescence during back-table FGI of the fresh surgical specimen and a 
corresponding tissue slice, showing fluorescence at the location of the luminal tumor, though low 
fluorescence near the CRM (A), which was confirmed during microscopic fluorescence imaging and 
correlated to histology (B). FFPE = formalin-fixed paraffin embedded; HE = hematoxylin eosin. 
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